Radiosensitization of glioblastoma cells using a histone deacetylase inhibitor (SAHA) comparing carbon ions with X-rays

References

• Barazzuol L, Burnet NG, Jena R, Jones B, Jefferies SJ, Kirkby NF. 2010. A mathematical model of brain tumour response to radiotherapy and chemotherapy considering radiobiological aspects. J Theor Biol 262:553–565.
   PubMed Web of Science ®Google Scholar
• Barazzuol L, Jena R, Burnet NG, Jeynes JCG, Merchant MJ, Kirkby KJ, Kirkby NF. 2011. In vitro evaluation of combined temozolomide and radiotherapy using X rays and high-linear energy transfer radiation for glioblastoma. Radiat Res 177:651–662.
   Web of Science ®Google Scholar
• Barazzuol L, Jena R, Burnet NG, Meira LB, Jeynes JCG, Kirkby KJ, Kirkby NF. 2013. Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. Radiat Oncol 8:65.
   PubMed Web of Science ®Google Scholar
• Barber P, Locke R, Pierce G, Rothkamm K, Vojnovic B. 2007. Gamma-H2AX counting: Image processing and control software for high content screening. Proc SPIE 6441:M–3.
   Google Scholar
• Bellucci L, Dalvai M, Kocanova S, Moutahir F, Bystricky K. 2013. Activation of p21 by HDAC inhibitors requires acetylation of H2A.Z. PLoS One 8:e54102.
   Web of Science ®Google Scholar
• Blattmann C, Oertel S, Ehemann V, Thiemann M, Huber PE, Bischof M, Witt O, Deubzer HE, Kulozik AE, Debus J, Weber K-J. 2010. Enhancement of radiation response in osteosarcoma and rhabomyosarcoma cell lines by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 78:237–245.
   PubMed Web of Science ®Google Scholar
• Camphausen K, Burgan W, Cerra M, Oswald KA, Trepel JB, Lee MJ, Tofilon PJ. 2004. Enhanced radiation-induced cell killing and prolongation of gamma H2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 64:316–321.
   PubMed Web of Science ®Google Scholar
• Chen X, Wong P, Radany EH, Stark JM, Laulier C, Wong JYC. 2012. Suberoylanilide hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma. Mol Cancer Res 10:1052–1064.
   PubMed Web of Science ®Google Scholar
• Chinnaiyan P, Chowdhary S, Potthast I, Prabhu A, Tsai Y, Sarcar B, Kahali S, Brem S, Yu H, Rojiani A, Murtagh R, Pan E. 2012. Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma. Neuro Oncol 14:93–100.
   PubMed Web of Science ®Google Scholar
• Conti C, Leo E, Eichler GS, Sordet O, Martin MM, Fan A, Aladjem MI, Pommier Y. 2010. Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res 70:4470–4480.
   PubMed Web of Science ®Google Scholar
• Dalgard CL, Van Quill KR, O’Brien JM. 2008. Evaluation of the In vitro and In vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. Clin Cancer Res 14:3113–3123.
   PubMed Web of Science ®Google Scholar
• Di Bernardo G, Alessio N, Dell’Aversana C, Casale F, Teti D, Cipollaro M, Altucci L, Galderisi U. 2010. Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells. J Cell Physiol 225:537–544.
   PubMed Web of Science ®Google Scholar
• Felsenfeld G, Groudine M. 2003. Controlling the double helix. Nature 421:448–453.
   PubMed Web of Science ®Google Scholar
• Friday B, Anderson S, Buckner J, Yu C, Giannini C, Geoffroy F, Schwerkoske J, Mazurczak M, Gross H, Pajon E, Jaeckle K, Galanis E. 2012. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: A north central cancer treatment group study. Neuro Oncol 14:215–221.
   PubMed Web of Science ®Google Scholar
• Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer B, Giannini C, Flynn PJ, Moore DFJ, Zwiebel J, Buckner JC. 2009. Phase II trial of vorinostat in recurrent glioblastoma multiforme: A north central cancer treatment group study. J Clin Oncol 27: 2052–2058.
   PubMed Web of Science ®Google Scholar
• Groselj B, Sharma NL, Hamdy FC, Kerr M, Kiltie AE. 2013. Histone deacetylase inhibitors as radiosensitisers: Effects on DNA damage and signalling repair. Br J Cancer 108:748–754.
   PubMed Web of Science ®Google Scholar
• Gui CY, Ngo l, Xu WS, Richon VM, Marks PA. 2004. Histone deacetylase (HDAC) inhibitor activation of p21(WAF1) involves changes in promoter-associated proteins, including HDAC1. PNAS 101: 1241–1246.
   PubMed Web of Science ®Google Scholar
• Hall EJ, Giaccia AJ. 2006. Radiobiology for the radiologist, 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins.
   Google Scholar
• Harikrishnan KN, Karagiannis TC, Chow MZ, El-Osta A. 2008. Effect of valproic acid on radiation-induced DNA damage in euchromatic and heterochromatic compartments. Cell Cycle 7:468–476.
   PubMed Web of Science ®Google Scholar
• Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PA, Steffan JS, Marsh JL, Thompson LM, Lewis CM, Marks PA, Bates GP. 2003. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. PNAS 100:2041–2046.
   PubMed Web of Science ®Google Scholar
• Horn S, Barnard S, Rothkamm K. 2011. Gamma-H2AX-based dose estimation for whole and partial body radiation exposure. PLoS One 6:e25113.
   PubMed Web of Science ®Google Scholar
• Kanai T, Endo M, Minohara S, Miyahara N, Koyama-Ito H, Tomura H, Matsufuji N, Futami Y, Fukumura A, Hiraoka T, Furusawa Y, Ando K, Suzuki M, Soga F, Kawachi K. 1999. Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy. Int J Radiat Oncol Biol Phys 44:201–210.
   PubMed Web of Science ®Google Scholar
• Kano M, Yamada S, Hoshino I, Murakami K, Akutsu Y, Sakata H, Nishimori T, Usui A, Miyazawa Y, Kamada T, Tsujii H, Matsubara H. 2009. Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma. Anticancer Res 29:4433–4438.
   PubMed Web of Science ®Google Scholar
• Kelly WK, O’Connor OA, Krug ML, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Scwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM. 2005. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923–3931.
   PubMed Web of Science ®Google Scholar
• LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD. 2009. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. 2009. BMC Med Genomics 2:67.
   PubMed Web of Science ®Google Scholar
• Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassma AB, Mcgovern RM, Xu J, Desideri S, Ye X, Ames MM, Espinoza-Delgado I, Prados MD, Wen PY. 2012. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res 18:6032–6039.
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci PG. 2006. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38–51.
   PubMed Web of Science ®Google Scholar
• Nakajima NI, Brunton H, Watanabe R, Shrikhande A, Hirayama R, Matsufuji N, Fujimori A, Murakami T, Okayasu R, Jeggo P, Shibata A. 2013. Visualisation of γH2AX foci caused by heavy ion particle traversal; distinction between core track versus non-track damage. PLoS One 8:e70107.
   PubMed Web of Science ®Google Scholar
• Oertel S, Thiemann M, Richter K, Weber K-J, Huber PE, Perez RL, Brons S, Bischof M, Kulozik AE, Ehemann V, Debus J, Blattmann C. 2011. Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines. Radiat Oncol 6:119.
   PubMed Web of Science ®Google Scholar
• Qiu L, Kelso MJ, Hansen C, West ML, Fairlie DP, Parsons PG. 1999. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 80: 1252–1258.
   PubMed Web of Science ®Google Scholar
• Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. 2000. PNAS 97: 10014–10019.
   PubMed Web of Science ®Google Scholar
• Roy S, Packman K, Jeffrey R, Tenniswood M. 2005. Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ 12:482–491.
   PubMed Web of Science ®Google Scholar
• Torikoshi M, Minohara S, Kanematsu N, Komori M, Kanazawa M, Noda K, Miyahara N, Itoh H, Endo M, Kanai T. 2007. Irradiation system for HIMAC. J Radiati Res 48:A15–A25.
   Web of Science ®Google Scholar
• Toth KF, Knoch TA, Wachsmuth M, Frank-Stohr M, Stohr M, Bacher CP, Muller G, Rippe K. 2004. Trichostatin A-induced histone acetylation causes decondensation of interphase chromatin. J Cell Sci 117:4277–4287.
   PubMed Web of Science ®Google Scholar
• Yin D, Ong JM, Hu J, Desmond JC, Kawamata N, Konda BM, Black KL, Koeffler HP. 2007. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: Effects of gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res 13: 1045–1052.
   PubMed Web of Science ®Google Scholar